Update on sentinel lymph node evaluation in gynecologic malignancies
Identifieur interne : 004A18 ( Main/Exploration ); précédent : 004A17; suivant : 004A19Update on sentinel lymph node evaluation in gynecologic malignancies
Auteurs : Katina Robison [États-Unis] ; Laura L. Holman [États-Unis] ; Richard G. Moore [États-Unis]Source :
- Current opinion in obstetrics & gynecology [ 1040-872X ] ; 2011.
Abstract
Sentinel lymph node (SLN) dissections have been shown to be sensitive for the evaluation of nodal basins for metastatic disease and are associated with decreased short-term and long-term morbidity when compared with complete lymph node dissection. There has been increasing interest in the use of SLN technology in gynecologic cancers. This review assesses the current evidence-based literature for the use of SLN dissections in gynecologic malignancies.
Recent literature continues to support the safety and feasibility of SLN biopsy for early-stage vulvar cancer with negative predictive value approaching 100% and low false-negative rates. Alternatively, for endometrial cancer most studies have reported low false-negative rates, with variable sensitivities and have reported low detection rates of the sentinel node. Studies examining the utility of SLN biopsy in early-stage cervical cancer remain promising with detection rates, sensitivities, and false-negative rates greater than 90% for stage 1B1 tumors.
SLN dissections have been shown to be effective and safe in certain, select vulvar cancer patients and can be considered an alternative surgical approach for these patients. For endometrial and cervical cancer, SLN dissection continues to have encouraging results and however needs further investigation.
Url:
PubMed: 21235023
PubMed Central: 4868087
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 003877
- to stream Pmc, to step Curation: 003876
- to stream Pmc, to step Checkpoint: 002C52
- to stream Ncbi, to step Merge: 004077
- to stream Ncbi, to step Curation: 004077
- to stream Ncbi, to step Checkpoint: 004077
- to stream Main, to step Merge: 004A50
- to stream Main, to step Curation: 004A18
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Update on sentinel lymph node evaluation in gynecologic malignancies</title><author><name sortKey="Robison, Katina" sort="Robison, Katina" uniqKey="Robison K" first="Katina" last="Robison">Katina Robison</name><affiliation wicri:level="4"><nlm:aff id="A1">Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region><settlement type="city">Providence (Rhode Island)</settlement></placeName><orgName type="university">Université Brown</orgName></affiliation></author><author><name sortKey="Holman, Laura L" sort="Holman, Laura L" uniqKey="Holman L" first="Laura L." last="Holman">Laura L. Holman</name><affiliation wicri:level="4"><nlm:aff id="A1">Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region><settlement type="city">Providence (Rhode Island)</settlement></placeName><orgName type="university">Université Brown</orgName></affiliation></author><author><name sortKey="Moore, Richard G" sort="Moore, Richard G" uniqKey="Moore R" first="Richard G." last="Moore">Richard G. Moore</name><affiliation wicri:level="4"><nlm:aff id="A2">Center for Biomarkers and Emerging Technologies, Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Biomarkers and Emerging Technologies, Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region><settlement type="city">Providence (Rhode Island)</settlement></placeName><orgName type="university">Université Brown</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">21235023</idno><idno type="pmc">4868087</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868087</idno><idno type="RBID">PMC:4868087</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">003877</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003877</idno><idno type="wicri:Area/Pmc/Curation">003876</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003876</idno><idno type="wicri:Area/Pmc/Checkpoint">002C52</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002C52</idno><idno type="wicri:Area/Ncbi/Merge">004077</idno><idno type="wicri:Area/Ncbi/Curation">004077</idno><idno type="wicri:Area/Ncbi/Checkpoint">004077</idno><idno type="wicri:doubleKey">1040-872X:2011:Robison K:update:on:sentinel</idno><idno type="wicri:Area/Main/Merge">004A50</idno><idno type="wicri:Area/Main/Curation">004A18</idno><idno type="wicri:Area/Main/Exploration">004A18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Update on sentinel lymph node evaluation in gynecologic malignancies</title><author><name sortKey="Robison, Katina" sort="Robison, Katina" uniqKey="Robison K" first="Katina" last="Robison">Katina Robison</name><affiliation wicri:level="4"><nlm:aff id="A1">Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region><settlement type="city">Providence (Rhode Island)</settlement></placeName><orgName type="university">Université Brown</orgName></affiliation></author><author><name sortKey="Holman, Laura L" sort="Holman, Laura L" uniqKey="Holman L" first="Laura L." last="Holman">Laura L. Holman</name><affiliation wicri:level="4"><nlm:aff id="A1">Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region><settlement type="city">Providence (Rhode Island)</settlement></placeName><orgName type="university">Université Brown</orgName></affiliation></author><author><name sortKey="Moore, Richard G" sort="Moore, Richard G" uniqKey="Moore R" first="Richard G." last="Moore">Richard G. Moore</name><affiliation wicri:level="4"><nlm:aff id="A2">Center for Biomarkers and Emerging Technologies, Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Biomarkers and Emerging Technologies, Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region><settlement type="city">Providence (Rhode Island)</settlement></placeName><orgName type="university">Université Brown</orgName></affiliation></author></analytic><series><title level="j">Current opinion in obstetrics & gynecology</title><idno type="ISSN">1040-872X</idno><idno type="eISSN">1473-656X</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Purpose of review</title><p id="P1">Sentinel lymph node (SLN) dissections have been shown to be sensitive for the evaluation of nodal basins for metastatic disease and are associated with decreased short-term and long-term morbidity when compared with complete lymph node dissection. There has been increasing interest in the use of SLN technology in gynecologic cancers. This review assesses the current evidence-based literature for the use of SLN dissections in gynecologic malignancies.</p></sec><sec id="S2"><title>Recent findings</title><p id="P2">Recent literature continues to support the safety and feasibility of SLN biopsy for early-stage vulvar cancer with negative predictive value approaching 100% and low false-negative rates. Alternatively, for endometrial cancer most studies have reported low false-negative rates, with variable sensitivities and have reported low detection rates of the sentinel node. Studies examining the utility of SLN biopsy in early-stage cervical cancer remain promising with detection rates, sensitivities, and false-negative rates greater than 90% for stage 1B<sub>1</sub> tumors.</p></sec><sec id="S3"><title>Summary</title><p id="P3">SLN dissections have been shown to be effective and safe in certain, select vulvar cancer patients and can be considered an alternative surgical approach for these patients. For endometrial and cervical cancer, SLN dissection continues to have encouraging results and however needs further investigation.</p></sec></div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Rhode Island</li></region><settlement><li>Providence (Rhode Island)</li></settlement><orgName><li>Université Brown</li></orgName></list><tree><country name="États-Unis"><region name="Rhode Island"><name sortKey="Robison, Katina" sort="Robison, Katina" uniqKey="Robison K" first="Katina" last="Robison">Katina Robison</name></region><name sortKey="Holman, Laura L" sort="Holman, Laura L" uniqKey="Holman L" first="Laura L." last="Holman">Laura L. Holman</name><name sortKey="Moore, Richard G" sort="Moore, Richard G" uniqKey="Moore R" first="Richard G." last="Moore">Richard G. Moore</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:4868087
|texte= Update on sentinel lymph node evaluation in gynecologic malignancies
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21235023" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |